Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 20/20 | 0.82 |
| ▸ | NR1I2 | O75469 | 5/20 | 0.82 |
| ▸ | PLK4 | O00444 | 1/20 | 0.82 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.82 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.82 |
| ▸ | JAK2 | O60674 | 1/20 | 0.82 |
| ▸ | ULK1 | O75385 | 1/20 | 0.82 |
| ▸ | ERN1 | O75460 | 1/20 | 0.82 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.82 |
| ▸ | ABL1 | P00519 | 1/20 | 0.82 |
| ▸ | KRAS | P01116 | 1/20 | 0.82 |
| ▸ | RAF1 | P04049 | 1/20 | 0.82 |
| ▸ | LCK | P06239 | 1/20 | 0.82 |
| ▸ | FYN | P06241 | 1/20 | 0.82 |
| ▸ | CDK1 | P06493 | 1/20 | 0.82 |
| ▸ | YES1 | P07947 | 1/20 | 0.82 |
| ▸ | LYN | P07948 | 1/20 | 0.82 |
| ▸ | MET | P08581 | 1/20 | 0.82 |
| ▸ | HCK | P08631 | 1/20 | 0.82 |
| ▸ | FGR | P09769 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1127161 | 0.94 | BRAF (0.75) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| SCHEMBL2193067 | 0.92 | BRAF (0.70) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| SCHEMBL2191410 | 0.91 | BRAF (0.69) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| SCHEMBL2193140 | 0.91 | BRAF (0.69) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| Dabrafenib SCHEMBL29353365 | 0.90 | BRAF (1.00) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| Dabrafenib SCHEMBL29350038 | 0.90 | BRAF (1.00) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| SCHEMBL1128208 | 0.90 | BRAF (0.81) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| Dabrafenib SCHEMBL806377 | 0.90 | BRAF (1.00) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| Dabrafenib SCHEMBL13739419 | 0.90 | BRAF (0.98) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| SCHEMBL20435084 | 0.90 | BRAF (0.80) | BRAFNR1I2PLK4EPHB6RIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303551-A1 | N-CYCLYL-SULFONAMIDES USEFUL FOR INHIBITING RAF | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2023-09-28 | — | — | US | disclosed |
| US-20230303551-A1 | N-CYCLYL-SULFONAMIDES USEFUL FOR INHIBITING RAF | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2023-09-28 | — | — | US | disclosed |
| WO-2022036176-A1 | N-CYCLYL-SULFONAMIDES USEFUL FOR INHIBITING RAF | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2022-02-17 | — | — | WO | disclosed |
| US-20160243118-A1 | COMBINATION OF BRAF AND VEGF INHIBITORS | NOVARTIS AG (CH) | 2016-08-25 | — | — | US | disclosed |
| US-20150352121-A1 | COMBINATION | GLAXOSMITHKLINE LLC (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150111904-A1 | PHARMACEUTICAL COMBINATION OF MEK INHIBITOR AND B-RAF INHIBITORS | NOVARTIS PHARMACEUTICALS CORPORATION | 2015-04-23 | — | — | US | disclosed |
| US-8835450-B2 | Combination of inhibitor of B-Raf and an inhibitor of Akt in the treatment of cancer | GLAXOSMITHKLINE LLC (US) | 2014-09-16 | — | — | US | disclosed |
| US-20130231347-A1 | METHOD OF TREATMENT WITH BRAF INHIBITOR | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2013-09-05 | — | — | US | disclosed |
| US-20130172378-A1 | Combination of BRAF and VEGF Inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-07-04 | — | — | US | disclosed |
| US-20120196886-A1 | COMBINATION | GLAXOSMITHKLINE LLC (US) | 2012-08-02 | — | — | US | disclosed |
| US-7994185-B2 | Benzene sulfonamide thiazole and oxazole compounds | Glaxo Smith Kline LLC (US) | 2011-08-09 | — | — | US | disclosed |
| US-20090298815-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303551-A1 | N-CYCLYL-SULFONAMIDES USEFUL FOR INHIBITING RAF | BRAF, RAF1, NRAS | BRAF 1/4885NR1I2 673/4885PLK4 1331/4885 |
| US-20130172378-A1 | Combination of BRAF and VEGF Inhibitors | BRAF, KDR, RAF1 | BRAF 1/4885NR1I2 3141/4885PLK4 821/4885 |
| US-20150352121-A1 | COMBINATION | BRAF, PIK3CA, RAF1 | BRAF 1/4885NR1I2 1674/4885PLK4 625/4885 |
| US-20130231347-A1 | METHOD OF TREATMENT WITH BRAF INHIBITOR | NRAS, BRAF, RAF1 | BRAF 2/4885NR1I2 4418/4885PLK4 1744/4885 |
| US-20120196886-A1 | COMBINATION | PAICS, FOLH1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | BRAF 564/4885NR1I2 3378/4885PLK4 3123/4885 |
| US-20150111904-A1 | PHARMACEUTICAL COMBINATION OF MEK INHIBITOR AND B-RAF INHIBITORS | BRAF, RAF1, ARAF | BRAF 1/4885NR1I2 3821/4885PLK4 924/4885 |
| US-20090298815-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | STS, TST, TPST2 | BRAF 776/4885NR1I2 886/4885PLK4 1205/4885 |
| US-20160243118-A1 | COMBINATION OF BRAF AND VEGF INHIBITORS | BRAF, KDR, RAF1 | BRAF 1/4885NR1I2 3095/4885PLK4 831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.